Gadolinium‑based contrast agents in neurofibromatosis type 1 (Review)

Năstase,Florentina; Radaschin,Diana Sabina; Niculeț,Elena; Stefanescu,Bogdan Ioan; Nechita,Aurel; Miruna,Draganescu; Baroiu,Liliana; Manuela,Arbune; Tatu,Alin Laurenţiu

doi:10.3892/etm.2021.9962

Gadolinium‑based contrast agents in neurofibromatosis type 1 (Review)

Authors:
- Florentina Năstase
- Diana Sabina Radaschin
- Elena Niculeț
- Bogdan Ioan Stefanescu
- Aurel Nechita
- Draganescu Miruna
- Liliana Baroiu
- Arbune Manuela
- Alin Laurenţiu Tatu
View Affiliations

Affiliations: Department of Neuropsychomotor Rehabilitation, ‘Sf. Ioan’ Clinical Hospital for Children, 800487 Galati, Romania, Clinical Department, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800010 Galati, Romania, Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800010 Galati, Romania, Research Center in the Field of Medical and Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800010 Galati, Romania, Department of Pediatrics, ‘Sf. Ioan’ Clinical Hospital for Children, 800487 Galati, Romania
Published online on: March 23, 2021 https://doi.org/10.3892/etm.2021.9962
Article Number: 530
Copyright: © Năstase et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gadolinium (symbol Gd) is the chemical element with atomic number 64 and is aductile rare‑earth metal, and +3 is its most frequent oxidation state. Gadolinium has an ionic radius of 0.99 Å and is nearly identical to the one of Ca²⁺. Gd³⁺ and Ca²⁺ can become toxic to biological systems if complete. It slowly reacts with atmospheric oxygen to form a black coating and in nature it is usually found only in an oxidized form. Gadolinium usually has impurities similar to those of other rare‑earth metals, when separated, because of their similar chemical properties. Neurofibromatosis type 1 (NF1) or von Recklinghausen's disease is an autosomal dominant disorder of tissues of ectodermal origin, accounting for over 90% of neurofibromatosis cases. Diagnosis is primarily clinical and the central nervous system is commonly involved. The screening of the brain with magnetic resonance (MR) imaging is utilised to evaluate the patients with neurofibromatosis type 1 and as an aid in the diagnosis of asymptomatic patients when clinical criteria are not met.

View Figures

View References

1	Tomonori K, Hiroshi O, Toyoda K and Kitajima K: Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol. 34:3–9. 2016.PubMed/NCBI View Article : Google Scholar
2	Sherry AD, Caravan P and Lenkinski RE: A primer on gadolinium chemistry. J Magn Reson Imaging. 30:1240–1248. 2009.PubMed/NCBI View Article : Google Scholar
3	Thomsen HS, Morcos SK, Almen T, Almén T, Bellin MF, Bertolotto M, Bongartz G, Clement O, Leander P, Heinz-Peer G, Reimer P, et al: Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 23:307–318. 2013.PubMed/NCBI View Article : Google Scholar
4	Bellin MF: MR contrast agents, the old and the new. Eur J Radiol. 60:314–323. 2006.PubMed/NCBI View Article : Google Scholar
5	Niendorf HP, Alhassan A and Balzer TH: Safety and risk of gadolinium-DTPA: Extended clinical experience after more than 20 million applications. Magn Monograph. 1–38. 1998.
6	Granata V, Cascella M, Fusco R, dell'Aprovitola N, Catalano O, Filice S, Schiavone V, Izzo F, Cuomo A, Petrillo A, et al: Immediate adverse reactions to gadolinium-based MR contrast media: A retrospective analysis on 10.608 examinations. Biomed Res Int. 2016(3918292)2016.PubMed/NCBI View Article : Google Scholar
7	Runge VM, Ai T, Hao D and Hu X: The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 46:807–816. 2011.PubMed/NCBI View Article : Google Scholar
8	Runge VM, Steward RG, Clanton JA, Jones MM, Lukehart CM, Partain CL and James AE Jr: Work in progress: Potential oral and intravenous paramagnetic NMR contrast agents. Radiology. 147:789–791. 1983.PubMed/NCBI View Article : Google Scholar
9	Hao D, Ai T, Goerner F, Hu X, Runge VM and Tweedle M: MRI contrast agents: Basic chemistry and safety. J Magn Reson Imaging. 36:1060–1071. 2012.PubMed/NCBI View Article : Google Scholar
10	The American College of Radiology. Manual on Contrast Media Version. Version 10.3.2018. Accessed from: http://www.acr.org/.
11	Ersoy H and Rybicki FJ: Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 26:1190–1197. 2007.PubMed/NCBI View Article : Google Scholar
12	Brănișteanu DE, Pintilie A, Dimitriu A, Cerbu A, Ciobanu D, Oanta A and Tatu AL: Clinical, laboratory and therapeutic profile of lichen planus. Medical Surgical J. 121:25–32. 2017.
13	Tatu AL, Ciobotaru OR, Miulescu M, Buzia OD, Elisei AM, Mardare N, Diaconu C, Robu S and Nwabudike LC: Hydrochlorothiazide: Chemical structure, therapeutic, phototoxic and carcinogenetic effects in dermatology. Rev Chim. 69:2110–2114. 2018.
14	Fekete GL and Fekete L: Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature. Exp Ther Med. 17:1128–1131. 2019.PubMed/NCBI View Article : Google Scholar
15	Ciobotaru OR, Lupu MN, Rebegea L, Ciobotaru OC, Earar K and Miulescu M: Dexamethasone-chemical structure and mechanisms of action in prophylaxis of postoperative side effects. Rev Chim. 70:843–847. 2019.
16	Tatu AL and Cristea VC: Unilateral blepharitis with fine follicular scaling. J Cutan Med Surg. 21(442)2017.PubMed/NCBI View Article : Google Scholar
17	Lupu M, Miulescu M, Sandu MN, Filip I, Rebegea L, Ciobotaru O, Stoleriu G, Earar K, Voinecsu CD, Oana R and Ciobotaru OR: Cannabinoids: Chemical structure, mechanisms of action, toxicity and implications in everyday life. Rev Chim. 70(627)2019.
18	Nwabudike LC, Elisei AM, Buzia OD, Miulescu M and Tatu AL: Statins. A review on structural perspectives, adverse reactions and relations with non-melanoma skin cancer. Rev Chim. 69:2557–2562. 2018.
19	Ardeleanu V, Dobre M and Georgescu AM: Deep facial wrinkle treatment outcome after first injection of reticulated hyaluronic acid. Rev Chim. 66:2129–2131. 2015.
20	Nwabudike L and Tatu AL: Response to - chronic exposure to tetracyclines and subsequent diagnosis for non-melanoma skin cancer in a large Mid-Western US population. J Eur Acad Dermatol Venereol. 32(e159)2018.PubMed/NCBI View Article : Google Scholar
21	Tatu AL, Ionescu MA and Nwabudike LC: Contact allergy to topical mometasone furoate confirmed by rechallenge and patch test. Am J Ther. 25:e497–e498. 2018.PubMed/NCBI View Article : Google Scholar
22	Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 45:575–578. 1988.
23	Antônio JR, Goloni-Bertollo EM and Trídico L: Neurofibromatosis: Chronological history and current issues. An Bras Dermatol. 88:329–343. 2013.PubMed/NCBI View Article : Google Scholar
24	Tatu AL and Nwabudike LC: The treatment options of male genital lichen sclerosus et atrophicus short title for a running head: Treatments of Genital Lichen Sclerosus Conference: 14th National Congress of Urogynecology (Urogyn)Location: Eforie, Romania Date: SEP 07-09, 2017. Proceedings of the 14th national congress of Urogynecology and the national conference of the Romanian association for the study of pain, pp262-264, 2017.
25	Nica SC, Mihailescu G, Nica SM, Baetu C, Clatici VG and Buruga I: Neurofibromatosis-one disease for a multidisciplinary team. RoJCED. 3:38–49. 2016.
26	Lund AM and Skobby F: Optic gliomas in children with neurofibromatosis type 1. Eur J Pediatr. 150:835–838. 1990.PubMed/NCBI View Article : Google Scholar
27	Elster AD: Radiologic screening in neurocutaneous syndromes: Strategies and controversies. AJNR Am J Neuroradiol. 13:1078–1082. 1992.PubMed/NCBI
28	Truhan AP and Filipek PA: Magnetic resonance imaging: Its role in the neuroradiologic evaluation of neurofibromatosis, tuberous sclerosis and Sturge-Weber syndrome. Arch Dermatol. 129:219–226. 1993.PubMed/NCBI View Article : Google Scholar
29	Bognanno JR, Edwards MK, Lee TA, Dunn DW, Roos KL and Klatte EC: Cranial MR imaging in neurofibromatosis. Am J Roentgenol. 151:381–388. 1988.PubMed/NCBI View Article : Google Scholar
30	Bonawitz C, Castillo M, Chin CT, Mukherji SK and Barkovich AJ: Usefulness of contrast material in MR of patients with Neurofibromatosis type 1. AJNR Am J Neuoradiol. 19:541–546. 1998.PubMed/NCBI
31	Tatu AL: Umbilicated blue black lesion on the lateral thorax. J Cutan Med Surg. 21(252)2017.PubMed/NCBI View Article : Google Scholar
32	Ardeleanu V, Frincu LL and Georgescu C: Neoangiogenesis-assessment in esophageal adenocarcinomas. Indian J Surg. 77 (Suppl 3):S971–S976. 2015.PubMed/NCBI View Article : Google Scholar
33	Ardeleanu V, Chebac GR, Georgescu C, Vesa D, Frâncu L, Frîncu LD and Păduraru D: The modifications suffered by the peri-esophageal anatomical structures in the hiatal hernia disease: A qualitative and quantitative microanatomic study. Rom J Morphol Embryol. 51:765–770. 2010.PubMed/NCBI
34	Fekete GL and Fekete JE: Steatocystoma multiplex generalizata partial suppurativa-case report. Acta Dermatovenerol Croat. 18:114–119. 2010.PubMed/NCBI